Dermatologic Diseases clinical trials at University of California Health

2 research studies open to eligible people

Showing trials for

  • Camoteskimab in Adults With Moderate to Severe Atopic Dermatitis

    open to eligible people ages 18-75

    This is a Phase 2a, multicenter, randomized, double-blind, placebo-controlled study with an open-label extension to evaluate the efficacy and safety of camoteskimab in adults with moderate to severe AD.

    at UCLA

  • Role of Angiogenesis in Dermatologic Diseases: A Potential Therapeutic Target

    open to eligible people ages 18 years and up

    The researchers believe that pro-angiogenic factors are upregulated in a wide range of dermatologic diseases including port wine stains, hemangiomas, angiofibromas, Kaposi's sarcoma, angiosarcoma, scars, rosacea and psoriasis. The researcher can perform immunohistochemistry and/or microarray analysis and/or quantitative polymerase chain reaction on previously biopsied skin specimens and newly biopsied skin specimens to evaluate the expression of various angiogenic factors in these dermatologic diseases. In addition, some of the skin specimens may be utilized to make cell cultures to study expression of angiogenic factors and interactions of cells in dermatologic disease.

    at UC Irvine

Our lead scientists for Dermatologic Diseases research studies include .

Last updated: